|
Jun 13
|
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
|
|
May 27
|
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
|
|
May 23
|
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
|
|
May 23
|
Outcome of Innate Pharma’s 2025 Annual General Meeting
|
|
May 19
|
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
|
|
May 15
|
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
|
|
May 13
|
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
|
|
May 12
|
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
|
|
Feb 17
|
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
|
|
Jan 10
|
Innate Pharma Announces Transformative Strategy to Accelerate Growth
|